Results 201 to 210 of about 25,638 (254)

Impurities and Potential Immunogenicity Associated With Follow-on and Compounded Glucagon-like Peptide-1 Receptor Agonists. [PDF]

Pharm Res
Kopp KL, Lamberth K, Schelde O, Øgendahl AK, Wojcieszek M, Mogensen JE, Ramírez-Andersen HS, Schneider CL, Staby A, Hach M.   +9 more
europepmc   +1 more source

Liraglutide Dose Affordability and Durability in Real‐World Obesity Care

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 6, November 2026.
Azhar Zafar, Carina Scarlata
wiley   +1 more source

The Effect of Behavioral Sleep Interventions on Measures of Obesity, Dietary Intake and Physical Activity in Adults With Poor Sleep Health: A Systematic Review, Meta‐Analysis and Meta‐Regression Analysis

Obesity Reviews, Volume 27, Issue 11, November 2026.
ABSTRACT Background As poor sleep negatively impacts on adiposity, there is interest in examining whether improving sleep can improve adiposity markers. We reviewed studies aimed at improving sleep using (1) cognitive behavioral therapy for insomnia (CBT‐I) and/or sleep hygiene and (2) sleep extension on adiposity markers, dietary intake, and physical ...
Samiul A. Mostafa, Pushpa Singh, Feaz Babwah, Wasim Hanif, George Balanos, Krishnarajah Nirantharakumar, Jason G. Ellis, Abd A. Tahrani   +7 more
wiley   +1 more source

Low Weight Loss Response to Incretin Analogs: A Systematic Review

Obesity Reviews, Volume 27, Issue 11, November 2026.
ABSTRACT The development of GLP‐1 and GIP analogs has been a significant breakthrough in type 2 diabetes and obesity pharmacotherapy. However, individual responses to these medications can vary widely. This systematic review examines factors associated with low or no weight loss response to GLP‐1 and GIP analogs. Key predictors of poor response include
Pamela S. Gaskin, Peter S. Chami
wiley   +1 more source

Liraglutide Potently Protects Against Streptozotocin-Induced Islet Injury Associated with Inhibition of HMGB1 Release. [PDF]

Cells
Shi Y, Yang X, Luo X, Yang J, Zhang Y, Chen G, Hou L.   +6 more
europepmc   +1 more source

GLP‐1 Receptor Agonists and Weight Loss: A Critical Review of Mechanisms

Obesity Reviews, Volume 27, Issue 11, November 2026.
ABSTRACT GLP‐1 receptor agonist medications have the potential to promote marked weight loss, but maximal and sustained benefit may be compromised by poor compliance and cessation of use. Development of next‐generation medications that address current obstacles to effective use and development of effective adjunct treatments will benefit from better ...
Giorgia Rutigliani, Tzu‐Wen L. Cross, Erica de Jong, Emily S. Glover, Ivan D. Mendoza, Mojisola Adisa, Keigo Tomoo, Xinyi Zhou, Richard D. Mattes   +8 more
wiley   +1 more source

Treatment of obesity with liraglutide in bipolar disorder: a case report. [PDF]

Front Psychiatry
Cipolla S, Vasca G, De Francesco D, Lombardo S, Delle Femine G, Volpicelli A, Perris F, Sampogna G, Luciano M.   +8 more
europepmc   +1 more source

Effects of Weight Loss Interventions on Gut Microbiota‐Derived Metabolites Linked to Cardiometabolic Health: A Systematic Review and Meta‐Analysis

Obesity Reviews, Volume 27, Issue 11, November 2026.
ABSTRACT Background Gut microbiota‐derived metabolites are emerging as potential mediators between obesity and cardiometabolic conditions. While weight loss interventions modify microbiota composition, their effects on systemic microbial metabolites remain unclear.
Fernando Q. Iorra, Leonardo André Swarowsky Loebens, Andrea Auler, Eduarda Caroline Tasso Nascimento, Beatriz D. Schaan, Patrícia Martins Bock   +5 more
wiley   +1 more source

Real-World Comparative Weight Loss of GLP-1 Receptor Agonists in the All of Us Research Program: A Retrospective Cohort Study. [PDF]

Drug Des Devel Ther
Hwang I, Lee SW, Kim Y.
europepmc   +1 more source